TBB
CAS No. 17374-26-4
TBB ( NSC 231634; Tetrabromobenzotriazole )
Catalog No. M12636 CAS No. 17374-26-4
TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 35 | In Stock |
|
10MG | 49 | In Stock |
|
25MG | 77 | In Stock |
|
50MG | 124 | In Stock |
|
100MG | 188 | In Stock |
|
200MG | 293 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTBB
-
NoteResearch use only, not for human use.
-
Brief DescriptionTBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
-
DescriptionTBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
-
SynonymsNSC 231634; Tetrabromobenzotriazole
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCK2; CDK2; GSK-3β
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number17374-26-4
-
Formula Weight434.71
-
Molecular FormulaC6HBr4N3
-
Purity>98%(HPLC)
-
SolubilityDMSO, Ethanol: 100 mM
-
SMILESBrC1=C(NN=N2)C2=C(Br)C(Br)=C1Br
-
Chemical Name4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Orzechowska E, et al. Oncol Rep. 2012 Jan;27(1):281-5.
molnova catalog
related products
-
Ocaperidona
Ocaperidona (Ocaperidone), a very high affinity dopamine D2antagonist.
-
IIIM-290
IIIM-290 is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively.
-
Ro-3306
Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.